The increase in the price target from $376 to $396 by Barclays suggests a positive outlook for HCA Healthcare. The Overweight rating indicates that the analyst expects the stock to outperform the market. This is likely to have a positive short-term impact on the stock price as investors may view the raised price target as a sign of confidence in the company's future performance.